Pharmaceuticals
Price
$65.47
+0.24%Market Cap
$133.37B
Day High
$68.10
Day Low
$64.14
In Q2 FY2026, Bristol-Myers Squibb delivered strong financial results with revenue growing 5.7% YoY to $12.97B and net income surging 153.2% YoY to $3.32B, driven by 15% growth in its new product portfolio and reduced Acquired IPRD charges.
Key risk: Accelerating Generic Patent Erosion
Loss of exclusivity and generic competition have significantly reduced revenues for legacy drugs such as Revlimid, Pomalyst, and Sprycel. Approaching patent expirations or biosimilar entries for key products like Eliquis and Orencia threaten ongoing top-line stability.
Other Pharmaceuticals companies